Kamada (NASDAQ:KMDA) Upgraded to Strong-Buy at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Kamada (NASDAQ:KMDA – Free Report) from a hold rating to a strong-buy rating in a research report report published on Saturday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Finally, William Blair set a $15.00 price target on shares of Kamada in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Check Out Our Latest Analysis on Kamada

Kamada Trading Up 4.4%

KMDA opened at $7.58 on Friday. The company has a fifty day moving average price of $7.22 and a two-hundred day moving average price of $7.96. Kamada has a 1-year low of $6.50 and a 1-year high of $9.35. The company has a market cap of $435.89 million, a P/E ratio of 19.95, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The company had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. On average, research analysts forecast that Kamada will post 0.45 EPS for the current fiscal year.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently modified their holdings of the business. Aristides Capital LLC increased its stake in shares of Kamada by 4.5% during the 4th quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 1,430 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Kamada by 4.2% in the third quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 2,125 shares during the last quarter. Barclays PLC lifted its stake in Kamada by 417.1% in the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 3,862 shares during the last quarter. Two Sigma Investments LP grew its holdings in Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares during the period. Finally, Man Group plc grew its holdings in Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,684 shares during the period. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

(Get Free Report)

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

Further Reading